iclaprim (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Acute Bacterial Skin and Skin Structure Infections

Pending FDA approval for treatment of acute bacterial skin and skin structure infections (ABSSSI)

Next:

Pharmacology

Mechanism of Action

Antibiotic; dihydrofolate reductase Inhibitor with a low propensity for resistance development and rapidly bactericidal in vitro

Inhibition of dihydrofolate reductase, inhibits folic acid reduction to tetrahydrofolate, causing inhibition of microorganism growth

Targeted spectrum of activity against Gram-positive bacteria, including MRSA

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.